-
Blog Post
Federal Circuit Holds Generic Drugs Manufactured in the U.S. from API Produced in India Qualify for Sale to U.S. under Trade Agreements Act (Acetris Decision)
Government Contracts Navigator -
Blog Post
GSA’s Big Changes in 2020, Part 5: The Mass Mod Is Coming, the Mass Mod Is Coming . . . Wait, It’s Here!
Government Contracts Navigator -
Blog Post
GSA’s Big Changes in 2020, Part 4: DUNS to UEI
Government Contracts Navigator -
Blog Post
GSA’s Big Changes in 2020, Part 3: With GSA’s Schedule Consolidation, What Is Changing and What Is Not
Government Contracts Navigator -
Media Coverage
Contract Clash Ruling Leaves Fraught Dispute to Congress
Law360 -
Blog Post
GSA’s Big Changes in 2020, Part 2: Category Management and the New Consolidated Schedule
Government Contracts Navigator -
Blog Post
GSA’s Big Changes in 2020, Part 1: Federal Supply Schedules Consolidation
Government Contracts Navigator -
Article
Federal Drug Pricing Transparency Efforts Outpace State Laws Requiring Drug Manufacturer Price Reporting for the First Half of 2019
Pratt’s Government Contracting Law Report -
Speaking Engagement
Agency Protests: An Emerging Tool and Potential Threat for Contractors
Celesq AttorneysEd Center and West LegalEd Center Webinar -
Alert
Real Estate Financing in the Healthcare Space: Keep Your Eye on the Ball
Real Estate